OwnershipPublicly listed · Nasdaq: DXCMSEC EDGAR company record and tickers file (Nasdaq: DXCM) · checked Oct 28, 2026
Commercial developmentNot yet assessedWe only state a stage once a source supports it. Having a product on sale does not show it works or makes money.
Investment accessVerified public listingListed as Nasdaq: DXCM, per the SEC's company tickers file. A listing means shares trade publicly; it says nothing about whether they are a good investment.Source · checked Oct 28, 2026
Evidence is labelled on each development below (company-reported, regulatory filing or government record), not on the company as a whole. Next scheduled recheck: Nov 27, 2026.
4developments published
—US federal obligations on record
0federal awards
Sep 10, 2026latest development
Timeline
- Sep 10, 2026 · Leadership change
Dexcom Appoints Glenn Boehnlein to Board of Directors
Company-reported - Sep 10, 2026 · Leadership change
Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Company-reported - Jul 30, 2026 · Reported results
Dexcom Reports Second Quarter 2026 Financial Results
Company-reported - May 27, 2026 · Shareholder vote
Dexcom reports results of a shareholder vote (Form 8-K, Item 5.07)
Regulatory filing
Profile
- Legal name
- DEXCOM INC
- Listing
- Nasdaq DXCM
- SEC filer
- CIK 0001093557 ↗
- SEC industry code
- Surgical & Medical Instruments & Apparatus
- Incorporated
- DE
- Coverage
- Filings + federal awards
Mix of developments
Watch Dexcom
Anything new from Dexcom lands in your digest, with the source beside it. Following is about information, never an investment action. Up to 10 companies or frontiers on Pro, $49/month.
Follow this companyPreview a sample digest